Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $58.00.

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Barclays upped their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a research note on Friday, May 22nd. Guggenheim upped their price objective on shares of Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, Evercore upped their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd.

Insider Buying and Selling

In other news, Director Robert Chess sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total value of $470,000.00. Following the completion of the sale, the director directly owned 21,084 shares of the company’s stock, valued at approximately $990,948. This represents a 32.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melissa A. Starovasnik sold 1,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the sale, the director directly owned 25,722 shares of the company’s stock, valued at $1,311,822. The trade was a 3.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,551 shares of company stock valued at $2,566,533 over the last ninety days. Company insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at about $31,000. Strs Ohio purchased a new stake in shares of Twist Bioscience in the first quarter valued at about $33,000. PNC Financial Services Group Inc. raised its holdings in shares of Twist Bioscience by 89.7% in the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after buying an additional 453 shares during the last quarter. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $28,000. Finally, Strategic Advocates LLC raised its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $66.87 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average price of $54.62 and a 200 day moving average price of $44.46. The company has a market cap of $4.16 billion, a P/E ratio of -50.28 and a beta of 2.22. Twist Bioscience has a 12 month low of $23.30 and a 12 month high of $71.04.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.66) EPS. Sell-side analysts predict that Twist Bioscience will post -1.86 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.